The 2019 novel coronavirus disease(coVID-19),causedby the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has occurred in China and around theworld.SARS-CoV-2-infected patients with severe pneu-monia rapid...The 2019 novel coronavirus disease(coVID-19),causedby the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has occurred in China and around theworld.SARS-CoV-2-infected patients with severe pneu-monia rapidly develop acute respiratory distress syn-drome(ARDS)and die of multiple organ failure.Despiteadvances in supportive care approaches,ARDS is stillassociated with high mortality and morbidity.Mes-enchymal stem cell(MSC)-based therapy may be anpotential alternative strategy for treating ARDS by tar-geting the various pathophysiological events of ARDS.By releasing a variety of paracrine factors and extra-cellular vesicles,MSC can exert anti-inflammatory,anti-apoptotic,anti-microbial,and pro-angiogenic effects,promote bacterial and alveolar fluid clearance,disruptthe pulmonary endothelial and epithelial cell damage,eventually avoiding the lung and distal organ injuries torescue patients with ARDS.An increasing number ofexperimental animal studies and early clinical studiesverify the safety and efficacy of MSC therapy in ARDS.Since low cell engraftment and survival in lung limitMSC therapeutic potentials,several strategies havebeen developed to enhance their engraftment in the lungand their intrinsic,therapeutic properties.Here,weprovide a comprehensive review of the mechanisms andoptimization of MSC therapy in ARDS and highlightedthe potentials and possible barriers of MSC therapy forcovID-19 patients with ARDS.展开更多
文摘The 2019 novel coronavirus disease(coVID-19),causedby the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has occurred in China and around theworld.SARS-CoV-2-infected patients with severe pneu-monia rapidly develop acute respiratory distress syn-drome(ARDS)and die of multiple organ failure.Despiteadvances in supportive care approaches,ARDS is stillassociated with high mortality and morbidity.Mes-enchymal stem cell(MSC)-based therapy may be anpotential alternative strategy for treating ARDS by tar-geting the various pathophysiological events of ARDS.By releasing a variety of paracrine factors and extra-cellular vesicles,MSC can exert anti-inflammatory,anti-apoptotic,anti-microbial,and pro-angiogenic effects,promote bacterial and alveolar fluid clearance,disruptthe pulmonary endothelial and epithelial cell damage,eventually avoiding the lung and distal organ injuries torescue patients with ARDS.An increasing number ofexperimental animal studies and early clinical studiesverify the safety and efficacy of MSC therapy in ARDS.Since low cell engraftment and survival in lung limitMSC therapeutic potentials,several strategies havebeen developed to enhance their engraftment in the lungand their intrinsic,therapeutic properties.Here,weprovide a comprehensive review of the mechanisms andoptimization of MSC therapy in ARDS and highlightedthe potentials and possible barriers of MSC therapy forcovID-19 patients with ARDS.
